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The heart’s response to varying demands of the body is regulated
by signaling pathways that activate protein kinases which phos-
phorylate sarcomeric proteins. Although phosphorylation of car-
diac myosin binding protein-C (cMyBP-C) has been recognized as a
key regulator of myocardial contractility, little is known about its
mechanism of action. Here, we used protein kinase A (PKA) and Ce
(PKCe), as well as ribosomal S6 kinase II (RSK2), which have differ-
ent specificities for cMyBP-C’s multiple phosphorylation sites, to
show that individual sites are not independent, and that phos-
phorylation of cMyBP-C is controlled by positive and negative reg-
ulatory coupling between those sites. PKA phosphorylation of
cMyBP-C’s N terminus on 3 conserved serine residues is hierarchical
and antagonizes phosphorylation by PKCe, and vice versa. In con-
trast, RSK2 phosphorylation of cMyBP-C accelerates PKA phos-
phorylation. We used cMyBP-C’s regulatory N-terminal domains
in defined phosphorylation states for protein–protein interaction
studies with isolated cardiac native thin filaments and the S2 do-
main of cardiac myosin to show that site-specific phosphorylation
of this region of cMyBP-C controls its interaction with both the
actin-containing thin and myosin-containing thick filaments. We
also used fluorescence probes on the myosin-associated regula-
tory light chain in the thick filaments and on troponin C in the
thin filaments to monitor structural changes in the myofilaments
of intact heart muscle cells associated with activation of myocar-
dial contraction by the N-terminal region of cMyBP-C in its differ-
ent phosphorylation states. Our results suggest that cMyBP-C acts
as a sarcomeric integrator of multiple signaling pathways that
determines downstream physiological function.
cardiac muscle regulation | myosin binding protein-C | phosphorylation
Contraction of cardiac muscle is initiated by activation of theactin-containing thin filaments, but is modulated by struc-
tural changes in the myosin-containing thick filaments. Calcium
binding to troponin induces an azimuthal movement of tropo-
myosin on the surface of the thin filaments which allows myosin
head domains from the neighboring thick filaments to strongly
attach to actin (1). Subsequently, small conformational changes
in the actin-attached myosin catalytic domain are amplified by
the essential and regulatory light chain-containing myosin light
chain domain or “lever arm” associated with the release of
Adenosine 5′-triphosphate hydrolysis products (2, 3). This “working
stroke” produces piconewton-scale force and nanometer-scale dis-
placement of the thin filaments toward the center of the sarcomere.
Heart muscle contractility is also regulated by posttranslational
modifications of sarcomeric proteins, including phosphorylation of
the regulatory components of the thick filaments (4). Phosphor-
ylation of these components has been widely implicated in the
regulation of cardiac output, and altered phosphorylation levels
have been frequently associated with heart failure (5), further
underlining their functional significance. In the current study, we
focused on phosphorylation of cardiac myosin binding protein-C
(cMyBP-C), a thick filament-associated protein with important
regulatory functions in both healthy and diseased states of the
heart. The functional significance of cMyBP-C phosphorylation is
highlighted by the fact that ablation of either cMyBP-C or its
phosphorylation leads to pathological hypertrophy in animal mod-
els, suggesting that cMyBP-C phosphorylation is essential for nor-
mal heart function (6, 7).
cMyBP-C is localized to 9 transverse stripes in the central
region of each half-thick filament, called the C-zone, via inter-
actions of its C-terminal anchoring region with the myosin tails
and titin (Fig. 1A), closely matching the ∼43-nm periodicity of
the myosin head domains. In contrast, interactions of its regu-
latory N-terminal domains are less well defined, and binding sites
for both myosin and actin have been identified in vitro (8).
Myosin interactions of cMyBP-C’s N terminus are generally asso-
ciated with an inhibitory effect on contractility, and both structural
and functional studies suggest that cMyBP-C stabilizes the thick
filament OFF state by tethering myosin head domains to the sur-
face of the thick filament backbone (9, 10). In contrast, cMyBP-C’s
N-terminal domains have also been shown to bind actin and acti-
vate the thin filament presumably by moving tropomyosin away
from its blocked position, which increases the calcium sensitivity of
its regulatory units (11, 12).
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Fig. 1. Hierarchical phosphorylation of C1mC2 by PKA. (A, Top) Diagram of the sarcomere. The thick filament D-, C-, and P-zones and M-line are labeled
accordingly. (A, Bottom) Domain organization and known protein interactions of cMyBP-C. The proline/alanine-rich linker (P/A) between domains C0 and
C1 and the m-motif (m) between domains C1 and C2 are labeled accordingly. Sequence alignment of the m-motif residues encompassing the conserved
phosphorylation sites (red) is shown below, with canonical PKA consensus sequences (RRXS) underlined. Serines are numbered according to the rat cMyBP-C
sequence. (B) Time (t)-dependent in vitro phosphorylation of C1mC2 by PKA analyzed by Phos-tag–SDS/PAGE. (C) Chromatogram demonstrating the sepa-
ration of phosphorylated C1mC2 constructs (0P, 1P, 2P, and 3P) by IEC on the Resource S column. Blue, green, and red traces correspond to phosphorylation
reactions stopped at different time points. (D) MS analysis of phosphorylated residues in IEC fractions shown in C. Example MALDI-MS/MS spectra for
tris-phosphorylated C1mC2 (C1mC2-3P, blue) and bis-phosphorylated C1mC2 (C1mC2-2P, green) are shown with peaks labeled with their corresponding
phosphorylated peptide sequences. Note that the peak at the 2,236.126 mass-to-charge ratio (m/z) corresponding to S313-phosphorylated peptide found in
C1mC2-3P is missing in the C1mC2-2P spectrum (indicated by a red box). The peak at 1,256.671 m/z is not shown in the C1mC2-2P spectrum for clarity. In-
terpretation of the MS data is summarized in the box on the right. Details are provided in text. In vitro kinase assays with S-A–substituted C1mC2 analyzed by
Phos-tag–SDS/PAGE (E) and deconvolution into phosphorylation of individual serine residues (F) are shown. Mean ± SEM (n = 6). Statistical significance of
differences between values was assessed with a one-way ANOVA followed by Tukey’s post hoc test: *P < 0.05, ***P < 0.001.
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Both the inhibitory and activating interactions of cMyBP-C are
believed to be controlled by its phosphorylation state. The car-
diac specific “m-motif” between domains C1 and C2 contains a
series of conserved serine residues that are phosphorylated by
several protein kinases in vivo and in vitro (13) (Fig. 1A). Pro-
tein kinase A (PKA) has been identified as the primary kinase
acting upon cMyBP-C (14), mediating some of the effects of
β-adrenergic stimulation on myocardial function, such as in-
creased cross-bridge kinetics, decreased calcium sensitivity, and
accelerated relaxation (15, 16). More recently, other protein
kinases have been shown to phosphorylate cMyBP-C with dis-
tinct specificities for m-motif serines, suggesting that each
phosphorylation site might have distinct regulatory effects (13).
However, the detailed function and mechanism underlying
cMyBP-C phosphorylation at individual sites remain poorly un-
derstood, likely due to the complexity of its interaction with
other sarcomeric components, which is further compounded by
the multiplicity of signaling pathways acting upon cMyBP-C and
its associated phosphorylation states (17). Current mechanistic
hypotheses of the effects of cMyBP-C phosphorylation are
largely based on in vivo experiments in animal models (6, 18) or
tissues derived from those animals (19) in which phosphorylation
levels and associated regulatory mechanisms cannot be con-
trolled at the molecular level. Moreover, serine-to-aspartate
substitutions have been frequently used as a convenient model
for phosphorylation, although recent studies showed that these
substitutions only partially recapitulate the effects of phosphor-
ylation (20). Conversely, in vitro experiments with fully phos-
phorylated proteins or proteins containing serine-to-aspartate
substitutions do not recapitulate the in vivo complexity of cMyBP-C’s
interactions and its dynamic phosphorylation (21–23).
The aim of the present work was to understand the molecular
mechanism of cMyBP-C phosphorylation and its structural and
functional effects on both thin and thick filament-based regula-
tion in heart muscle cells. We investigated the relationship of
individual cMyBP-C phosphorylation sites and potential cross-talk
using several protein kinases known to phosphorylate cMyBP-C.
We utilized cMyBP-C fragments with well-characterized phos-
phorylation states to show that site-specific phosphorylation has
distinct effects on its interaction with and regulation of the thin
and thick filaments, combining in vitro biochemical binding assays
with in situ structural measurements in intact heart muscle cells.
The results show that cMyBP-C acts as a sarcomeric integrator of
different signaling pathways to determine downstream physiological
effects, and that the functional effects of cMyBP-C phosphorylation
can only be understood by combining thin and thick filament-based
mechanisms into an integrated model of contractile regulation.
Results
Hierarchical Phosphorylation of cMyBP-C by PKA. To elucidate the
regulatory function of cMyBP-C phosphorylation, we phosphory-
lated a recombinant fragment of rat cMyBP-C containing domains
C1, the phosphorylatable m-motif, and C2 (C1mC2; Fig. 1A) with
the catalytic subunit of PKA in vitro (Fig. 1B). The C1mC2 frag-
ment is a convenient model for studying the function of full-length
cMyBP-C, particularly with respect to its effects on both thin and
thick filament structure (11, 12, 20) and its regulation by phos-
phorylation (20, 24, 25). Although rodent and human C1mC2 have
a high sequence identity (>92%), suggesting a conserved molec-
ular function, species-specific effects cannot be excluded (26).
Incubation of C1mC2 for 30 to 60 min with PKA resulted
in a mixture of unphosphorylated, monophosphorylated, bis-
phosphorylated, and tris-phosphorylated protein, which could be
clearly separated by both Phos-tag and sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS/PAGE) (Fig. 1B).
Individual C1mC2 phospho-species were isolated by stopping the
kinase reaction at different time points and separating the
phosphorylated proteins by ion-exchange chromatography (IEC)
(Fig. 1C). The phosphorylation level and homogeneity (>95%)
of each IEC fraction (e.g., 1P, 2P, 3P) were confirmed by elec-
trospray ionization (ESI) mass spectrometry (MS) (SI Appendix,
Table S1). Tetrakis-phosphorylated C1mC2 was only observed
after prolonged incubation with PKA at 30 °C, suggesting that
the fourth site is a poor substrate for PKA.
Phosphorylated amino acid residues in each IEC fraction were
identified by proteolytic digestion followed by phospho-peptide
enrichment and matrix-assisted laser desorption ionization (MALDI)
MS and ESI-MS (SI Appendix, Fig. S1) (details are provided in SI
Appendix, Supplementary Information Methods). Analysis of the
IEC fraction corresponding to monophosphorylated C1mC2
(C1mC2-1P) revealed specific phosphorylation on a single serine
residue, S288, in agreement with previous studies suggesting that
S288 in the cardiac-specific insertion is the initial PKA phos-
phorylation site (14). Bis-phosphorylated C1mC2 (C1mC2-2P)
contained phosphorylated serine residues only in positions 288
and 279, and tris-phosphorylated C1mC2 (C1mC2-3P) contained
phosphorylated serines only in positions 288, 279, and 313. As an
example, the MALDI-MS spectrum of C1mC2-3P is shown in Fig.
1D, with peaks corresponding to identified phospho-peptides la-
beled accordingly. The peak at a 2,236.126 mass-to-charge ratio
corresponding to the S313-phosphorylated peptide is missing in
the MALDI-MS spectrum of the bis-phosphorylated C1mC2
(C1mC2-2P) (Fig. 1 D, Inset, Top Left, red box), suggesting that
S313 is phosphorylated after S288 and S279. In contrast, phos-
phorylation of S308 by PKA was only observed after prolonged
incubation, suggesting that this serine is a poor substrate for PKA
in vitro. Thus, our results suggest that PKA phosphorylation of the
cardiac-specific m-motif follows a concerted hierarchical mecha-
nism in the sequence of S288, followed by S279, followed by S313
(Fig. 1 D, Inset, Top Right).
To further test this conclusion, we prepared serine-to-alanine
(S-A) substitutions of each individual PKA site in C1mC2, and
analyzed their phosphorylation profiles by Phos-tag–SDS/PAGE
(Fig. 1E). Total phosphate incorporation after 60 min of in-
cubation was strongly reduced in S288A-substituted C1mC2
(1.25 ± 0.08 mol of inorganic phosphate [Pi]/mol [mean ± SEM];
n = 6; SI Appendix, Fig. S2) compared with wild type (2.94 ±
0.18 mol of Pi/mol [mean ± SEM]; n = 6). S279A- and S313A-
substituted C1mC2 showed intermediate levels of phosphorylation,
although S279A had a stronger inhibitory effect than S313A (1.6 ±
0.11 and 2.17 ± 0.12 mol of Pi/mol, respectively), in agreement with
the hierarchical phosphorylation sequence proposed above.
Next, we analyzed the effects of S-A substitutions on phos-
phate incorporation by PKA at each individual phosphorylation
site (Fig. 1F). Consistent with the hierarchical model, phos-
phorylation of S288 was not significantly affected by substitution
of either S279 or S313 by alanine. Similarly, S279 phosphoryla-
tion was not inhibited by substitution of either S288 or S313 by
alanine, although in the native fragment, this residue is phos-
phorylated after S288. This suggests that unphosphorylated
S288 may be involved in intramolecular interactions that prevent
access to S279, and that substitution of S288 by alanine abolishes
this interaction. If so, substitution of S288 by alanine might
therefore partially mimic phosphorylation of this site. In con-
trast, S313 phosphorylation was inhibited by substitution of ei-
ther S288 or S279 to alanine, further supporting the proposal
that this residue is phosphorylated downstream of S288 and S279.
Contrary to the effects of S-A substitutions described above, PKA
phosphorylation of S308 was greatly increased in C1mC2-S313A
(∼50%) compared with wild-type control (∼10%), suggesting that
phosphorylation of S313 per se has an inhibitory effect on phos-
phorylation of S308.
cMyBP-C Phosphorylation by Non-PKA Kinases Reveals Regulatory
Coupling of Phosphorylation Sites. Although PKA is considered
to be the primary kinase acting upon cMyBP-C in vivo, several








other kinases have been shown to be able to phosphorylate specific
residues within the cardiac-specific m-motif (13). Moreover, these
kinases have been frequently shown to be activated during heart
disease, underlining their functional significance.
Ribosomal S6 kinase II (RSK2) has been suggested to spe-
cifically phosphorylate serine residues in the cardiac-specific m-
motif insertion in response to activation of the mitogen-activated
protein kinase/extracellular signal-regulated kinase pathway
(27), and we used site-specific S-A substitution and MS to con-
firm these results (Fig. 2A and SI Appendix, Fig. S3). RSK2
primarily phosphorylated rat C1mC2 at S288 in vitro, although
we observed phosphorylation of other residues at higher enzyme-
to-substrate ratios or after prolonged incubation. In contrast,
α-adrenergic stimulation leads to an increase in cMyBP-C
phosphorylation primarily via stimulation of protein kinase Ce
(PKCe) (28, 29) [and protein kinase D (PKD) (30)] activity. We
used site-directed mutagenesis, MS, and Western blot analysis to
confirm that PKCe specifically phosphorylates S308 in C1mC2 in
vitro (Fig. 2 B and C and SI Appendix, Fig. S3). Phosphorylation
of S288 was not a prerequisite for phosphorylation of S308 by
PKCe as shown previously (31).
Next, we investigated potential cross-talk between cMyBP-C–
mediated phosphorylation by RSK2, PKCe, and PKA using pu-
rified C1mC2 fragments site-specifically phosphorylated by RSK2
and PKCe as substrates in PKA kinase assays. As expected from
the sequential phosphorylation of C1mC2 described above, S288
phosphorylation by RSK2 significantly accelerated phosphoryla-
tion of S279 by PKA, but had no effect on phosphorylation of
residues downstream of S279 (i.e., S313) (Fig. 2 D and E). In
contrast, phosphorylation of S308 by PKCe decreased the rate of
PKA phosphorylation of S313, suggesting that S308P is a negative
regulator of cMyBP-C PKA phosphorylation of S313, consistent
with previous results in isolated cardiomyocytes (32). Moreover,
both S288 by RSK2 and S308 by PKCe phosphorylation reduced
overall phosphate incorporation into C1mC2 by PKA by ∼1 mol
of Pi/mol of C1mC2 (Fig. 2F). Although this is expected for
phosphorylation of S288 as a main PKA site, S308 is primarily
phosphorylated by PKCe and PKD, further confirming the an-
tagonistic effects of PKA- and PKCe/PKD-mediated phosphory-
lation of cMyBP-C.
In summary, the multiple cMyBP-C phosphorylation sites are
not independent, and exhibit positive and negative regulatory
coupling with partially overlapping specificity for multiple kinases.
Site-Specific Phosphorylation Controls Thick and Thin Filament
Binding of C1mC2. To characterize the effects of site-specific
cMyBP-C phosphorylation on its proposed interactions with both
the myosin-containing thick and actin-containing thin filaments
(12, 20), we determined the binding affinities of C1mC2 in its
different phosphorylation states for isolated myosin S2 and na-
tive thin filaments (NTFs) in vitro. The affinity of C1mC2 for its
binding site on myosin, the first 126 amino acids of myosin S2
(S2Δ), was characterized by microscale thermophoresis (MST).
As previously shown, unphosphorylated C1mC2 binds S2Δ in a
biphasic manner, corresponding to high- and low-affinity binding
sites with dissociation constants (Kds) of 20.7 ± 3.5 μmol/L
(mean ± SEM; n = 6) and >400 μmol/L, respectively (20).
Moreover, the Kd for myosin S2Δ of λ-protein phosphatase–
treated native full-length cMyBP-C isolated from rat ventricular
tissue was 24.2 ± 3.9 μmol/L (mean ± SEM; n = 4) (SI Appendix,
Fig. 2. C1mC2 phosphorylation by RSK2 and PKCe. (A) RSK2-mediated phosphorylation of S288 in rat C1mC2 was confirmed by in vitro kinase (IVK) assays
using wild-type and S288A- substituted C1mC2 as well as MALDI-MS phosphorylation site profiling. m/z, mass-to-charge ratio. (B) PKCe phosphorylation of
S308 in rat C1mC2was confirmed by both IVK assays using phosphoablated C1mC2-S308D and ESI-MS. (C) Western blot analysis of RSK2- and PKCe-phosphorylated
C1mC2 using PKA site (RRXpS)-specific and S288 (pS288)-specific antibodies. Note that PKCe-phosphorylated C1mC2 is not recognized by either of the antibodies,
confirming S308 as the main phosphorylation site. (D) PKA IVK assays with unphosphorylated, S288-phosphorylated, or S308-phosphorylated C1mC2 analyzed by
Phos-tag–SDS/PAGE. t, time. Analysis of individual site phosphorylation (E) and total level of phosphate incorporation by PKA (F) are shown. Mean ± SEM (n = 3 to
9). Statistical significance of differences between values was assessed with a one-way ANOVA followed by Tukey’s post hoc test: *P < 0.05, **P < 0.01.
4 of 10 | www.pnas.org/cgi/doi/10.1073/pnas.1903033116 Ponnam et al.
Fig. S4), in good agreement with the results obtained for
recombinant rat C1mC2.
Monophosphorylation of either S308 or S288 slightly reduced
C1mC2’s affinity for myosin S2Δ as indicated by an increase in
Kd to ∼30 μmol/L (Fig. 3A and SI Appendix, Fig. S5 and Table
S2). In contrast, both PKA bis-phosphorylation (S288 and S279)
and tris-phosphorylation (S288, S279, and S313) completely
abolished S2Δ binding, indicating that either bis-phosphorylation
or phosphorylation of S279 per se controls the cMyBP-C–myosin
S2 interaction. We addressed this question by phosphorylating
C1mC2-S288A with PKA and isolating the monophosphorylated
species (C1mC2-S288A-1P) using IEC. Both unphosphorylated
and monophosphorylated C1mC2-S288A bind myosin S2Δ with
a Kd similar to that measured for the wild-type protein (Kd of
∼20 μmol/L), suggesting that bis-phosphorylation is necessary
and sufficient to abolish cMyBP-C–myosin S2 interaction (Fig.
3B and SI Appendix, Table S2). To further test this conclusion,
we sequentially phosphorylated C1mC2 with RSK2 and PKCe,
and measured the affinity of the bis-phosphorylated C1mC2
(S288 and S308) for myosin S2Δ (SI Appendix, Fig. S6). The
RSK2/PKCe bis-phosphorylated C1mC2 did not bind to myosin
S2Δ, further supporting the hypothesis that bis-phosphorylation
per se, independent of the phosphorylation site combination,
abolishes cMyBP-C–myosin S2 interaction. These results are
consistent with the largely ionic nature of cMyBP-C’s main in-
teraction site in the m-motif and myosin S2 (20).
We measured the affinity of C1mC2 in its different phos-
phorylation states for isolated bovine cardiac NTFs using high-
velocity cosedimentation. Unphosphorylated C1mC2 (0P) binds
NTFs in the absence of calcium (pCa 9) in a saturable manner
with a Kd of ∼20 μmol/L and a maximal binding capacity (Bmax)
of ∼1, indicating stoichiometric binding of C1mC2 to actin (Fig.
3 C–F and SI Appendix, Fig. S5 and Table S2). Addition of cal-
cium (pCa 4.5) had no effect on C1mC2 binding to NTFs as
indicated by identical Kd and Bmax values (Fig. 3 D–F and SI
Appendix, Fig. S5A and Table S2). Strikingly, both PKA mono-
phosphorylation (S288) and bis-phosphorylation (S288 and
S279), as well as monophosphorylation of S308 by PKCe, showed
no change in the affinity of C1mC2 for NTFs (Kd ∼ 20 μmol/L),
but decreased Bmax to ∼0.5, suggesting a lower binding capacity
of C1mC2 in the partially phosphorylated states. As before, full
calcium activation of NTFs had no additional effect on either Kd
or Bmax. However, PKA tris-phosphorylation (3P) significantly
decreased C1mC2’s affinity for NTF with an estimated Kd of
∼60 μmol/L independent of [Ca2+]. Addition of calcium increased
Bmax from ∼0.5 to ∼1 for C1mC2-3P, suggesting an interplay
between tris-phosphorylation of C1mC2, thin filament binding,
and calcium activation (23).
These results suggest that cMyBP-C phosphorylation regulates
contractility partly via differential modulation of its affinity for
myosin and actin binding sites, so that phosphorylation leads to a
redistribution of cMyBP-C’s N-terminal domains from their
myosin binding sites in the thick filaments to their actin binding
sites in the thin filaments. Monophosphorylation weakens and
bis-phosphorylation abolishes thick filament binding, and only tris-
phosphorylation affects C1mC2 binding to regulated thin filaments.
Site-Specific Phosphorylation of C1mC2 Controls Its Effect on Thin and
Thick Filament Structure. Next, we used a bifunctional rhodamine
probe attached to the E-helix of cardiac troponin C (cTnC-E) to
monitor structural changes in the thin filaments of demembra-
nated ventricular muscle cells associated with the activating ef-
fect of C1mC2 described previously (12). Unphosphorylated
C1mC2 activates the force and thin filament structure of ven-
tricular trabeculae in the absence of Ca2+ (pCa 9) with a half-
maximal effective concentration (EC50) of ∼20 μmol/L (Fig. 4A,
filled red circles). Maximum isometric force at [C1mC2] = 40
μmol/L is only ∼60% of that measured during Ca2+ activation in
the absence of C1mC2 (Fig. 4B), although the level of thin fil-
ament activation as reported by the cTnC probe is significantly
higher, suggesting that exogenous C1mC2 has both activating
and inhibitory effects on contractility.
PKA phosphorylation of S288 reduced the activating effect of
40 μmol/L C1mC2 on active force to ∼30% of that measured
during control conditions (Fig. 4B, light blue, 1P), to less than
10% after PKA bis-phosphorylation (C1mC2-2P, dark blue,
2P), and active force was completely abolished for PKA tris-
phosphorylated C1mC2 (C1mC2-3P) (Fig. 4B, purple). In con-
trast, S308 phosphorylation by PKCe did not inhibit the activating
effect of C1mC2 on force generation (Fig. 4B, yellow), suggesting
different regulatory functions of phosphorylation of S288 and S308.
The effects on isometric force described above are mirrored by
those on the thin filament structure as monitored by the cTnC-E
probe orientation. C1mC2 “superactivates” the thin filament as
indicated by a change in the order parameter <P2>, which is
significantly larger than that observed for calcium activation
Fig. 3. Effects of site-specific phosphorylation on binding of C1mC2 to
myosin S2Δ and NTFs. (A) Normalized MST curves for C1mC2 and its different
phosphorylation states titrated against myosin S2Δ. (B) NormalizedMST binding
curves for C1mC2-S288A (brown) and C1mC2-S288A-1P (black) titrated against
myosin S2Δ. NTF cosedimentation data for C1mC2 and its different phosphor-
ylation states in the absence (C, pCa 9) and presence (D, pCa 4.5) of 32 μmol/L
CaCl2 are shown. Calculated Kd (E) and Bmax (F) values for the NTF binding as-
says in the absence (filled circles) and presence (open circles) of CaCl2 are shown.
Mean ± SEM (n = 4 to 10). Statistical significance of difference was assessedwith
a one-way ANOVA followed by Tukey’s post hoc test: *P < 0.05, **P < 0.01.








alone (∼120%) (Fig. 4C). PKA monophosphorylation reduced
the activating effect to ∼30% of that measured during control
conditions in the absence of C1mC2, in agreement with the force
data. In contrast, S308 monophosphorylated C1mC2 showed an
intermediate effect on thin filament activation, corresponding to
∼70% of the control value (Fig. 4C, yellow). Incubation of
ventricular trabeculae with either 40 μmol/L PKA bis- or tris-
phosphorylated C1mC2 had no significant effect on thin filament
structure in the absence of Ca2+.
These results are in stark contrast to the NTF binding data
described above, suggesting that although phosphorylation of
cMyBP-C has only minor effects on its binding to the thin fila-
ment, it significantly alters thin filament regulation. Recent
electron microscopy studies demonstrated that N-terminal do-
mains of cMyBP-C bind polymorphically to isolated actin fila-
ments, and that only a subset of binding modes can directly
interfere with tropomyosin’s position and induce the ON state of
the thin filament (33, 34). The comparison suggests that cMyBP-
C phosphorylation regulates thin filament activation by altering
the equilibrium between binding states that affect tropomyosin’s
position on actin and those that do not.
Structural changes in the thick filament associated with the
activation of ventricular trabeculae by C1mC2 in its different
phosphorylation states were monitored using a bifunctional sul-
forhodamine probe cross-linking helices B and C in the myosin
regulatory light chain (BSR-cRLC-BC) (35). BSR-cRLC-BC is
localized close to the myosin S1/S2 junction and is mainly sen-
sitive to the regulatory state of the thick filament; the order
parameter <P2> from this probe increases upon calcium acti-
vation. In contrast to its effect on thin filament structure de-
scribed above, C1mC2 incubation leads to a partial activation of
the thick filament structure corresponding to ∼70% of that
measured during control activations (pCa 4.5; Fig. 4A, orange
open circle). Moreover, C1mC2 activated the thick filament with
a significantly lower EC50 than that measured for force or thin
filament activation (∼10 μmol/L; Fig. 4A, open red circles).
Monophosphorylation of either S288 by PKA or S308 by
PKCe showed no significant reduction in the activating effect of
40 μmol/L C1mC2 on the thick filament structure as reported by
the BC probe orientation (Fig. 4D), in contrast to the strong
reduction in thin filament activation and isometric force pro-
duction associated with phosphorylation of S288 (Fig. 4 B and C;
1P). Thus, although S288 phosphorylation and S308 phosphor-
ylation have similar effects on the regulatory state of the thick
filament, they have very different effects on the regulatory state
of the thin filament. In agreement with their effects on force and
thin filament structure, both C1mC2-2P and C1mC2-3P had no
significant effect on thick filament structure as measured by the
RLC BC probe orientation, consistent with the abolished binding
of C1mC2 to myosin S2Δ after PKA bis-phosphorylation and
tris-phosphorylation (Fig. 3A and SI Appendix, Table S2).
The comparison of the effects of C1mC2 in its different
phosphorylation states on the myosin head conformation with the
MST binding data described above further suggests that C1mC2
has a direct activating effect on the thick filament and that the
activating effect is, in turn, controlled by its phosphorylation-
dependent affinity for myosin S2Δ.
Site-Specific Phosphorylation of C1mC2 Controls Actomyosin ATPase
Activity. We further investigated the functional consequences of
site-specific C1mC2 phosphorylation on actomyosin interactions
by measuring the NTF-stimulated adenosinetriphosphatase
(ATPase) activity of isolated bovine myosin S1 in the presence of
C1mC2 in its different phosphorylation states using a colori-
metric assay (Fig. 5A).
Unphosphorylated C1mC2 activates the NTF-stimulated my-
osin S1 ATPase in the absence of calcium in a concentration-
dependent manner (Fig. 5B, red) and data points were fitted to
an activation/inhibition model as previously described (36). Low
concentrations activate phosphate production with an EC50
of ∼1 μmol/L and a Hill coefficient of ∼1.5, suggesting cooper-
ative activation of NTFs by C1mC2. In contrast, [C1mC2] >
2 μmol/L inhibits the ATPase activity with a half-maximal
inhibitory concentration (IC50) of ∼3 μmol/L. PKA mono-
phosphorylation (Fig. 5B, light blue) and bis-phosphorylation
(Fig. 5B, dark blue) of C1mC2 increased the EC50 of the acti-
vating effect further to ∼2 and ∼5 μmol/L, respectively, and tris-
phosphorylated C1mC2 did not activate actomyosin S1 ATPase
within the concentration range tested (Fig. 5B, purple). In fact,
C1mC2-2P and C1mC2-3P showed an inhibitory effect on the
actomyosin S1-ATPase in the concentration range of 1 to
4 μmol/L, presumably by competing with myosin S1 for binding
sites on actin. In contrast, during full calcium activation (Fig. 5C,
pCa 4), C1mC2 largely inhibits myosin S1-NTF ATPase activity
with an IC50 of ∼2 μmol/L and a maximal inhibition of ∼50% (Fig.
5C, red), similar to the values measured in the absence of Ca2+ and
[C1mC2] > 2 μmol/L. PKA phosphorylation of C1mC2 decreased
the amplitude of inhibition without affecting its IC50.
The direct comparison with the NTF binding data (Fig. 3 and
SI Appendix, Table S2) further supports the conclusion that
C1mC2 interacts with NTF in different binding modes and that
phosphorylation controls the distribution between states with in-
hibitory and activating effects. Surprisingly, [C1mC2-3P] < 2 μmol/L
Fig. 4. Effects of site-specific phosphorylation of C1mC2 on active force
and thin and thick filament structure in ventricular trabeculae. (A)
Concentration-dependent effect of C1mC2 on force generation (black
squares) and thin (red filled circles) and thick (red open circles) filament struc-
ture in ventricular trabeculae. TnC and RLC probe orientations are expressed as
the order parameter <P2>, which is +1 for a probe dipole orientation parallel
to the filament axis and −0.5 for a perpendicular orientation. <P2> for full
calcium activation is shown in orange on the left axis. (B) Isometric force of
ventricular trabeculae in the presence of 40 μmol/L C1mC2 in its different
phosphorylation states. ACT, activating solution (pCa 4.5); REL, relaxing solu-
tion (pCa 9). TnC (C) and RLC (D) probe orientations of ventricular trabeculae in
the presence of 40 μmol/L C1mC2 in its different phosphorylation states are
shown. Mean ± SEM, with the number of trabeculae (n), is indicated in each
panel. Statistical significance of differences between groups was assessed with
a one-way ANOVA followed by Tukey’s post hoc test: *P < 0.05, **P < 0.01,
***P < 0.001. ns, not significant.
6 of 10 | www.pnas.org/cgi/doi/10.1073/pnas.1903033116 Ponnam et al.
increased the NTF-stimulated myosin S1 ATPase in the presence
of calcium (pCa 4), consistent with its increased binding capacity
for NTFs in presence of Ca2+ described above and recent evidence
for antagonistic effects of phosphorylation and Ca2+ on cMyBP-C
structure (23).
Discussion
cMyBP-C Coordinates Thin and Thick Filament Activation in the Heart.
Multiple conserved phosphorylation sites have been identified in
close proximity to each other within cMyBP-C’s regulatory m-
motif (13). Moreover, each phosphorylation site is a substrate for
a different set of protein kinases, suggesting that cMyBP-C might
act as a central signaling hub within the sarcomere, integrating
different signaling pathways to control contractile function. Our
results strongly support a model in which phosphorylation of
cMyBP-C is controlled by regulatory coupling between individual
phosphorylation sites, and that different sites and combinations
thereof have distinct regulatory functions. According to this
model, activation of protein kinases downstream of cellular sig-
naling pathways results in a distinct cMyBP-C phosphorylation
pattern that alters heart muscle contractility by modulating both
(i) the distribution of cMyBP-C’s N-terminal domains (NcMyBP-C)
between binding sites in the thin and thick filaments and (ii) the
structure and associated regulatory state of the filaments.
The present results, in agreement with those of a wide range
of previous studies, suggest that in the unphosphorylated state,
cMyBP-C’s regulatory N-terminal domains interact with both the
actin-containing thin and myosin-containing thick filaments with
Kds in the micromolar range (21, 22, 33). We estimated the ef-
fective concentrations of cMyBP-C and of available actin and
myosin binding sites in the C-zone using the geometric con-
straints imposed by the modular architecture of cMyBP-C and
the myofilament lattice as about 150, 600, and 300 μmol/L, re-
spectively (SI Appendix, Supplementary Information Text and Fig.
S7). All of the effective concentrations are significantly larger
than the measured micromolar Kds, suggesting that the fraction
of “free” or unbound cMyBP-C in the filament lattice is very low,
and that the majority of NcMyBP-Cs are bound to either actin or
myosin (Fig. 6 and SI Appendix, Fig. S7). Moreover, although
C1mC2 binds NTFs and myosin S2Δ with similar affinity, the
higher local concentration of available actin binding sites pre-
dicts that a larger fraction will be bound to the thin filaments.
This conclusion is consistent with electron microscopy recon-
structions of resting skeletal muscle demonstrating links between
thick and thin filaments with an axial periodicity of ∼43 nm, as
expected for MyBP-C (37).
In the current study, we used soluble fragments of rat cMyBP-
C’s N-terminal domains as a model system to investigate the
structural and functional effects of its phosphorylation on both
thin and thick filament-based regulatory mechanisms. Fragment-
based experiments do have significant limitations. Truncations
might have led to the loss of protein interactions present in full-
length cMyBP-C; for example, domain C0 and the P/A-linker,
which are not present in the C1mC2 fragment used in the current
work, have been shown to enhance the functional effects of
cMyBP-C via interaction with both actin and myosin (34, 38).
Moreover, exogenous fragments are not subject to the stoichio-
metric and spatial limitations of endogenous cMyBP-C, and can
potentially occupy all possible binding sites within the sarcomere.
In contrast, in the intact heart, the effects of cMyBP-C and its
phosphorylation are limited to the ∼400-nm-wide C-zone, al-
though they are likely to be communicated to the adjacent D-
and P-zones via cooperative interactions in the thin and thick
filament structures (12). The former is associated with the end-
to-end interaction of tropomyosin molecules between adjacent
thin filament regulatory units, and the latter is associated with
interactions of myosin head domains in the OFF state (39, 40).
Exogenous cMyBP-C fragments might affect myofilament func-
tion by direct activating or inhibitory interactions, or by com-
peting with endogenous cMyBP-C for available binding sites, and
the current results help to further clarify this issue. We have
previously shown that C1mC2 retains its activating effect on the
thin filament in the absence of strong binding cross-bridges (12),
and the activation of isolated NTF-stimulated myosin S1 ATPase
by C1mC2 shows that this effect is not solely mediated by changes
in the thick filament structure. These results therefore strongly
suggest that both C1mC2 and, by extension, endogenous cMyBP-
C have a direct activating effect on the thin filament. In contrast,
C1mC2 activates the thick filament, with a significantly lower EC50
than that measured for force or thin filament activation (Fig. 5A).
Moreover, although C1mC2 retains its activating effect on thick
filament structure after phosphorylation at either S288 or S308
(Fig. 4D), phosphorylation at both sites reduces thin filament
activation, and S288 phosphorylation largely abolishes isometric
force production of ventricular trabeculae. Taken together, this
makes it highly unlikely that C1mC2’s effect on the thick filament
is solely mediated via thin filament activation followed by com-
munication of the activation signal from thin to thick filament or
through force generation per se, but is rather based on a direct
interaction with myosin. This conclusion is consistent with the
finding that serine-to-aspartate substitutions in C1mC2 abolish
myosin S2Δ binding and reduce thick filament activation without
affecting thin filament activation or force generation (20). It fol-
lows that C1mC2 fragments that bind to myosin S2Δ have a direct
activating effect on the thick filament, independent of any effect
on thin filament activation or force generation. It seems therefore
Fig. 5. Effect of site-specific phosphorylation of C1mC2 on actomyosin ATPase. (A) Effect of C1mC2 on NTF activation in vitro was estimated by measuring
the apparent rate constant of steady-state myosin S1-NTF ATPase activity (kobs). In the absence of Ca
2+ (green, pCa 9), the NTF-stimulated myosin S1 ATPase is
low (∼0.6 s−1), but it significantly increases in the presence of C1mC2 (red). In contrast, at saturating [Ca2+] (orange, pCa 4), the NTF-stimulated myosin S1
ATPase activity is high (∼3 s−1), but it decreases in the presence of C1mC2 (brown). t, time. The concentration dependence of the effect of C1mC2 in its
different phosphorylation states on the myosin S1-NTF ATPase in the absence (B) and presence (C) of calcium is shown. Data points were fitted to an acti-
vation/inhibition model yielding EC50 and IC50.








more likely that C1mC2’s activating effect on the thick filament is
due to a direct competition with the endogenous cMyBP-C, which
stabilizes the thick filament OFF state via interactions with the
S2 region of myosin, although an alternative mechanism involving
a direct effect of C1mC2 on the myosin head domains cannot be
excluded by the present results. Therefore, endogenous cMyBP-C
and exogenous C1mC2 have the same effect on the thin filament
but opposite effects on the thick filament.
We may therefore consider a dephosphorylated state of
cMyBP-C, in which about two-thirds of NcMyBP-Cs are bound
to the thin filament, locally increasing the calcium sensitivity of
its regulatory units in the C-zone (11, 12). The whole thin fila-
ment would, however, remain OFF during diastolic conditions
due to the low fraction of actins bound to NcMyBP-C. In con-
trast, the remaining one-third of NcMyBP-Cs are bound to
available myosin binding sites, and the consequence of this mode
of action of cMyBP-C is the stabilization of the thick filament
OFF state, characterized by myosin head domains arranged in
helical tracks on the thick filament surface (9) (Fig. 6A). The
largely calcium-independent affinity of C1mC2 for NTFs further
suggests that NcMyBP-C’s interactions with thin filaments are
retained during systolic calcium activation. According to this
concept, systolic increase in intracellular calcium concentration
([Ca2+]i) would first activate thin filament regulatory units op-
posite the C-zone, allowing individual myosin head domains to
strongly attach to actin. However, most myosin heads would
remain OFF due to inhibitory interactions of NcMyBP-C with
myosin S2. As more and more thin filament regulatory units in
the C-zone are switched ON, the fraction of actin-attached cross-
bridges increases, and a combination of structural changes in the
myosin head domains and cMyBP-C would trigger the activation
of additional myosin heads. At higher [Ca2+]i, the rest of the thin
filaments would become activated (12). According to this hy-
pothesis, the C-zone itself acts as a sarcomeric signaling element
that coordinates thin and thick filament activation, and therefore
myocardial contractility.
PKA Phosphorylation of cMyBP-C Activates Thick Filaments and
Inhibits Thin Filaments. The heart’s inotropic and lusitropic re-
sponse to β-adrenergic receptor stimulation is, in part, mediated
by PKA phosphorylation of cMyBP-C on key sites within the
cardiac-specific m-motif (14). The present results strongly
suggest that PKA sequentially phosphorylates these sites within
cMyBP-C so that the strength of the β-adrenergic stimulus
correlates with its phosphorylation profile. Although the
structural basis for this concerted mechanism of phosphoryla-
tion is currently unknown, it is likely that phosphorylation of
the initial site changes the conformation of subsequent sites so
that they are better recognized by the kinase. Consistent with
this hypothesis, a structural reorganization of cMyBP-C’s N-
terminal domains upon PKA phosphorylation has been ob-
served by both electron microscopy (23) and site-directed
spectroscopy (41).
PKA monophosphorylation weakens and bis-phosphorylation
abolishes C1mC2–myosin S2Δ interactions, suggesting that
S279 is the most important PKA site for regulating cMyBP-C’s
interaction with myosin S2 without, however, affecting its affinity
for NTFs. Thus, PKA phosphorylation promotes thin filament
binding of cMyBP-C by breaking the thick filament interaction of
its N-terminal domains with myosin S2, associated with a release
of myosin head domains from the filament backbone and acti-
vation of the thick filament (9, 15, 42) (Fig. 6 and SI Appendix,
Fig. S8). The functional consequence is a faster systolic acti-
vation of contraction, because myosin heads are no longer con-
strained by cMyBP-C and can bind to activated thin filament
regulatory units. According to our model, even a modest re-
duction in the affinity of the m-motif for myosin S2 via PKA
monophosphorylation is sufficient to cause reorientation of a
significant fraction of myosin-bound cMyBP-Cs (∼30%) toward
their actin binding sites. Although those represent a small fraction
of cMyBP-C molecules, we have previously presented evidence
that the regulatory transition in the thick filaments is highly co-
operative, so that activation of a small fraction of myosin heads
(<20%) can activate the whole thick filament structure (35).
In contrast, the redistribution of cMyBP-C’s N-terminal do-
mains toward the thin filament is believed to locally stabilize
its ON state, increase myocardial calcium sensitivity in vitro (11,
12, 36), and prolong the ejection phase and impair relaxation in
animal models in vivo (43). In contrast to the phosphorylation-
dependent interaction with myosin S2, the largely phosphorylation-
insensitive interaction of C1mC2 with NTFs and the high local
concentration of available actin binding sites suggests that almost
all of the PKA bis-phosphorylated and tris-phosphorylated
cMyBP-C will be bound to the thin filaments (Fig. 6B). How-
ever, PKA phosphorylation inhibits C1mC2’s activating effect on
thin filament structure (Fig. 4C), implying that increased thin fil-
ament binding of cMyBP-C upon phosphorylation is counteracted
by a simultaneous weakening of its activating effect, reducing
Fig. 6. Proposed model for the effects of site-specific cMyBP-C phos-
phorylation on thin and thick filament-based regulation. (A, Left) In the
dephosphorylated state, some cMyBP-C molecules (blue) are bound to
myosin S2 via their N-terminal domains, stabilizing the thick filament OFF
state in which the majority of myosin heads (brown) are folded back
against the thick filament backbone. The N terminus of other cMyBP-Cs are
bound to the thin filaments (gray), which increases the calcium sensitivity
of its regulatory units by moving tropomyosin away from its blocked po-
sition (troponin/tropomyosin in the ON state are indicated in orange). (A,
Right) Calculated distribution of cMyBP-C’s N-terminal domains bound to
either thin (A, gray) or thick (M, orange) filaments. The fraction of un-
bound cMyBP-C is indicated in purple. (B, Top) PKA phosphorylation dis-
rupts the cMyBP-C–myosin S2 interaction so that almost all cMyBP-C
molecules are bound to the thin filament (gray), which activates the
thick filament structure (indicated by brown myosin head domains). PKA
phosphorylation also abolishes the sensitizing effect of cMyBP-C on the
thin filament by modulating the conformation of cMyBP-C’s N-terminal
domains so that its regulatory units are in the OFF state (green ovals de-
pict deactivated troponins). (B, Middle) RSK2 phosphorylation of
S288 partially activates the thick filament, but almost completely inhibits
cMyBP-C’s activating effect on the thin filament. (B, Bottom) PKCe-
mediated (or PKD-mediated) phosphorylation of S308 partially activates
the thick filament structure by reducing cMyBP-C’s affinity for myosin S2.
However, S308 phosphorylation does not inhibit the sensitizing effect of
cMyBP-C on the thin filament regulatory units. (C ) Diagram summarizing
the proposed effects of site-specific cMyBP-C phosphorylation on thin
(gray) and thick (orange) filament-based regulation, and regulatory cou-
pling between individual phosphorylation sites. The specificity of protein
kinases for cMyBP-C phosphorylation sites is indicated by black arrows.
Inhibitory and activating effects of individual phosphorylation sites on
thin and thick filament regulation are indicated by red and green arrows,
respectively. More details are provided in text.
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calcium sensitivity (15) and facilitating relaxation (44). In contrast
to the intermediate effect on the thick filament described above,
monophosphorylation is sufficient to reduce the activating effect
of C1mC2 to ∼30% of that measured for unphosphorylated
C1mC2 (Fig. 4C), suggesting that S288 is the main regulator of
cMyBP-C’s effect on thin filament activation. Bis-phosphorylation
further reduces (to ∼10%) and tris-phosphorylation com-
pletely abolishes C1mC2’s activating effect on thin filament
structure as measured by cTnC probe orientation. This nonlinear
response to cMyBP-C phosphorylation is consistent with the pro-
gressive decrease in C1mC2’s ability to activate NTF-stimulated
myosin S1 ATPase after sequential phosphorylation of the 3 PKA
sites (Fig. 5B).
Taken together with the hierarchical order of phosphorylation
sites discussed above, these results suggest that β-adrenergic
stimulation mainly reduces thin filament calcium sensitivity via
PKA phosphorylation of S288, which subsequently facilitates
phosphorylation of S279 and activation of the thick filament
(Fig. 6).
Serine 288 is also phosphorylated by RSK2 (Fig. 2A), and it
was previously shown that RSK2-mediated in situ phosphoryla-
tion of cMyBP-C in skinned ventricular trabeculae increases
cross-bridge kinetics and decreases calcium sensitivity (27),
consistent with the S288-mediated partial activation of the thick
filament structure and inhibition of the thin filament structure
proposed here (Fig. 6B).
In summary, cMyBP-C exists in different regulatory states
depending on its phosphorylation profile, suggesting that cardiac
myofilament function is fine-tuned by the relative distribution of
cMyBP-C between its different phosphorylation states (e.g., 0P,
1P, 2P, 3P). According to this model, even moderate changes in
basal levels of cMyBP-C phosphorylation would have significant
functional consequences for the myocardium.
PKCe Phosphorylation of cMyBP-C Increases Thick Filament Activation
without Inhibiting the Thin Filament. In contrast, phosphorylation
of S308 does not abolish the activating effect of C1mC2 on thin
filament or force development, but similarly reduces its affinity
for myosin S2Δ. Thus, phosphorylation of S308 in cMyBP-C is
predicted to partially activate the thick filament C-zone without
the associated deactivation of the thin filament structure (Fig.
6B). The consequence would be significantly faster systolic ac-
tivation of contraction, since myosin head domains would be
readily available for interaction with the calcium-activated thin fila-
ment regulatory units inside the C-zone. Both PKCe and PKD have
been shown to phosphorylate S308 in vivo and in vitro, suggesting a
direct link between α-adrenergic receptor stimulation (45, 46),
S308 phosphorylation, and the inotropic response of the heart.
Consistent with this idea, PKD phosphorylation of trabeculae
from transgenic mouse lines expressing S22A/S23A-substituted
cardiac troponin I showed an increase in cross-bridge kinetics,
without an associated decrease in calcium sensitivity (30).
CamKII has been shown to be an important regulator of
cMyBP-C function, and, recently, CamKII-mediated phosphor-
ylation of S308 has been implicated in the positive force-frequency
relation of cardiac muscle (47), suggesting that the molecular
pathway described above for S308 phosphorylation by PKCemight
also be triggered by CamKII.
Functional Implications for Pathophysiology of Contractile Regulation
in the Heart. The phosphorylation-dependent interactions of
cMyBP-C have important implications for the physiology and
pathophysiology of contractile regulation in the heart, and the
current results show that cMyBP-C functions as an integrator of
multiple signaling elements that mediate context-specific functions
of the myocardium in health and disease. Dephosphorylation of
cMyBP-C has been frequently observed during heart failure (17),
likely associated with myocardial β-adrenergic receptor desensiti-
zation, and the present results suggest that the depressed force-
generating capacity and impaired relaxation are, in part, mediated
by dephosphorylated cMyBP-C stabilizing the thick and thin fila-
ment OFF and ON states, respectively.
Of particular interest in the heart failure setting is the RSK2-
mediated phosphorylation of S288, which partially mimics the
structural and functional effects of β-adrenergic stimulation and
primes S279 for phosphorylation by PKA (Fig. 2D) (and po-
tentially by other kinases [e.g., CamKII]). Similar to RSK2,
α-adrenergic receptor stimulation has been proposed as an al-
ternative pathway to unlock the inotropic reserve of the failing
heart (45), and our results suggest that PKD/ PKCe-mediated
phosphorylation of cMyBP-C increases contractile force via
direct activation of the thick filament. Although either RSK2
or PKD/PKCe phosphorylation only partially mimics the effects of
β-adrenergic signaling, phosphorylation by both kinases mimics
PKA bis-phosphorylation and abolishes the C1mC2–myosin S2Δ
interaction, suggesting that the combination of both pathways
might constitute a more effective heart failure treatment.
The concept of modulating the distribution of cMyBP-C’s
N-terminal domains between inhibitory binding sites in the thick
filaments and activating binding sites in the thin filaments has wider
implications for the regulation of cardiac contractility. Other sig-
naling pathways such as RLC phosphorylation or length-dependent
activation, the cellular analog of the Frank–Starling law of the
heart, might act through a similar mechanism by disrupting cMyBP-
C–myosin interactions and favoring binding of the N-terminal do-
mains of cMyBP-C to the thin filament. From the perspective of
the well-known mechanisms of cardiac muscle regulation, the
current results therefore require a paradigm shift that integrates
both thin and thick filament-based mechanisms into a single model
of contractile regulation, with a key role for cMyBP-C.
Methods
Protein production and phosphorylation, preparation of cardiac trabeculae,
protein exchange protocols, and fluorescence polarization experiments were
performed according to published protocols. Details of materials and
methods are provided in SI Appendix, Supplementary Information Methods.
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